Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

A new study showed that SOCS1 regulation of GM-CSF signaling is dose-dependent. The study, which involved generating a novel ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

Cells producing interleukin-6 (IL-6) and the actions of IL-6 in the body. Ig = immunoglobulin, CRP = C-reactive protein, SAA = serum amyloid A protein. Reprinted, with permission, from reference 21.

The three-signal paradigm tries to capture how the innate immune system instructs adaptive immune responses in three well-defined actions: (1) presentation of antigenic peptides in the context of MHC ...

Interleukin Inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a CAGR of 12.6%. BURLINGAME, CA, UNITED STATES, December 18, ...

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomized, single-blind pilot study. Ann. Rheum.

belle.shiga-med.ac.jp Background and aim: Interleukin (IL) 17 is a cytokine which exerts strong proinflammatory activities. In this study we evaluated changes in IL-17 expression in the inflamed ...

Background—In the lipopolysaccharide (LPS) stimulated peripheral blood monocyte, the precursor form of interleukin 1β (IL-1β, 31 kD) is processed by IL-1β converting enzyme (ICE) to the mature, ...

Although RA is associated with significant morbidity, the increasing number of effective drugs and modes of action has improved the disease outcome. Currently, several US Food and Drug Administration ...

The authors' work 3, however, primarily highlights the role of memory B-cell IL-10 in downregulating the active inflammatory response in EAE (that is, disease remission), less so the role of B ...